Calcium, Vitamin D & the Drug Tier
The supplement aisle promises to fix bones in a capsule; the evidence says the answer is mostly food, and when food is not enough the next step is not a bigger bottle but a different tier entirely. This page sorts the stack in order of honesty: what diet can do, what the vitamin D and calcium trials actually found, and when medication becomes the answer.
What the evidence supports
- Food-first calcium meets needs in most people; supplements have not reduced fractures in community-dwelling adults (Zhao et al., JAMA, 2017).
- Vitamin D corrects deficiency — and beyond correcting deficiency, routine supplementation has not cut fracture risk in large trials.
- Bone medications produce large, reproducible fracture reductions in high-risk people — vertebral fractures falling by roughly 47–73% across pivotal trials.
What remains uncertain
- The long-term safety balance of decades-long treatment — drug holidays and sequencing are still being refined.
- Whether supplemental calcium carries a small cardiovascular cost — meta-analyses disagree.
- How to personalize start and stop points — risk thresholds are population tools applied to individuals.
Evidence last reviewed: August 15, 2026. Conclusions may change as new research is published.
when medication becomes the answer
Calcium: The Raw-Material Problem
The skeleton holds about 99% of the body's calcium — roughly a kilogram of it — and blood calcium is defended ferociously, because nerves and muscle need it in a tight range. When dietary calcium runs short, parathyroid hormone rises and orders the remodeling crews to release calcium from bone. Chronic shortfall, in other words, is a slow raid on the ledger the first page in this series describes. The intake target that keeps the raid off is 1,000 mg a day for women under 50 and 1,200 mg a day after 50 (Institute of Medicine, Dietary Reference Intakes, 2011). The word "intake" does the work here: the target is a food target, and the trial evidence repeatedly failed to find that reaching it by pill helps — a point the parent topic's calcium callout owns in detail.
Where the Calcium Lives
Three servings of dairy — or fortified equivalents — lands most women at the target without arithmetic. Approximate amounts, from standard food composition data:
| Food | Typical serving | Calcium | Read |
|---|---|---|---|
| Milk (dairy or fortified soy/oat) | 1 cup | ≈ 300 mg | Solid |
| Yogurt | 6–8 oz | ≈ 250–400 mg | Solid |
| Hard cheese | 1 oz | ≈ 200 mg | Solid |
| Sardines, with bones | 3 oz | ≈ 325 mg | Solid |
| Calcium-set tofu | ½ cup | ≈ 250–430 mg, varies by brand | Varies |
| Cooked kale or collards | 1 cup | ≈ 100 mg, well absorbed | Partial |
| Spinach | 1 cup cooked | ≈ 245 mg, mostly locked up by oxalate | Misleading |
Spinach earns its verdict honestly: its oxalate binds calcium so tightly that only a small fraction is absorbed — a reminder that the label number and the absorbed number are different quantities. Leafy greens are superb foods; they are simply not a calcium strategy on their own.
Vitamin D: The Absorption Cofactor
Vitamin D is what lets the gut absorb calcium efficiently — a genuine deficiency (<20 ng/mL by the Endocrine Society's convention) is worth correcting, and correction clearly helps the deficient. The recommended intake is 600 IU a day to age 70 and 800 IU after (Institute of Medicine, 2011). Where the evidence gets honest is above that floor: in the VITAL trial, 2,000 IU daily in over 25,000 midlife and older adults did not reduce fractures (LeBoff et al., New England Journal of Medicine, 2022), and a large Australian trial of monthly high-dose vitamin D reached the same null (Neale et al., Lancet Diabetes & Endocrinology, 2022). One caution even underlines the point: an annual megadose of 500,000 IU actually increased falls and fractures in one trial (Sanders et al., JAMA, 2010). The policy follows: test when risk factors warrant it, correct a deficiency, and skip the megadose theater. An older finding survives as the one nuance — combined calcium plus vitamin D appeared to reduce hip fractures in frail, institutionalized older adults who were commonly deficient — which is a story about treating deficiency in the most at-risk, not about routine supplementation for everyone else.
The Supplement Honesty, In One Paragraph
The meta-analytic bottom line has been stable for nearly a decade: calcium or vitamin D supplements have not been associated with fewer fractures in community-dwelling adults (Zhao et al., JAMA, 2017), a systematic review found that raising calcium intake by food or pill does not reduce fracture risk (Bolland et al., BMJ, 2015), and a possible small cardiovascular signal with calcium supplements reported in some meta-analyses remains debated rather than settled. None of this makes supplements dangerous for someone closing a measured gap; it makes them what the parent topic says: gap-fillers, not insurance. The skeleton's better friends are on the plate and in the gym — the two pages immediately behind this one.
When Medication Becomes the Answer
Medication enters when the ten-year arithmetic from the Fracture Math page crosses a line, not when a supplement bottle runs out. In practice, treatment is generally indicated when any of these is true: a hip or vertebral fracture has already occurred (the strongest indication of all — the imminent risk window is real), the T-score is −2.5 or below, or the FRAX probability reaches about 20% for major osteoporotic fracture or 3% for hip (US National Osteoporosis Foundation thresholds). Within that group, the medications are among the better-proven treatments in all of chronic-disease medicine — the chart shows the vertebral-fracture results from the pivotal trials:
The Drug Classes, Tier by Tier
Four classes carry the modern conversation. They differ in mechanism, schedule, and where they sit in a treatment sequence:
| Class | How it works | Typical schedule | Verdict |
|---|---|---|---|
| Bisphosphonates (alendronate, zoledronate) | Slow the demolition crew — the workhorse anti-resorptives, decades of data | Weekly pill or yearly infusion | First-line |
| Denosumab | Antibody against RANKL — pauses resorption; strong adherence | Six-monthly injection | Alternative |
| Romosozumab | Dual action — builds bone while slowing resorption | Monthly injection, about one year | High risk |
| Teriparatide | Anabolic — directly stimulates the builders | Daily injection, up to two years | Specialist |
Two notes complete the picture. Bisphosphonates sit first because they are effective, cheap, and long-studied; the anabolic agents are usually reserved for the highest-risk patients or when first-line treatment stalls. And hormone therapy, covered honestly by the WHI-corrected topic, genuinely preserves bone — but it is chosen for the whole woman at the right window, not prescribed for bone alone. None of the tiers above is a do-it-yourself shelf; the next section is the fine print.
The Fine Print: Holidays, Rebound, and Rare Harms
Osteoporosis therapy is a sequence managed over years, not a course you finish — and the sequencing rules are where damage is most often done:
- ⏸️ Bisphosphonate holidays are real. After three to five years, if risk has dropped, a planned pause is standard — the drug lingers in bone and protection persists for a while. This is a clinician's call, timed to the risk, not a self-directed experiment.
- 🚫 Denosumab has no holiday. Stopping it without follow-on therapy causes rapid rebound bone loss and an increased risk of vertebral fractures — the transition off is planned from the start, and it is the clearest "never stop on your own" rule in this tier.
- 🦵 The rare harms are rare and worth knowing. Osteonecrosis of the jaw is uncommon at osteoporosis doses, and atypical thigh-bone fractures appear at low rates with long-term use — new thigh or groin pain on treatment is a report-it symptom.
- 🧭 Sequencing beats loyalty. Current practice often builds first with an anabolic and holds with an anti-resorptive — a planned handoff that is, again, clinician territory through and through.
⚠️ The drug tier is clinician territory
Everything in this tier is a prescription medicine with real rare harms and sequencing rules — and none of the thresholds on this page are a self-service checkout. If your risk crosses into treatment territory, the decision about starting, switching, or stopping belongs in a clinician's office. Never start or stop any of these agents on your own; with denosumab especially, an unplanned stop is its own injury.
Questions, Answered Briefly
- 🥛 Should I be taking a calcium pill "just in case"? No — the trials say insurance calcium doesn't prevent fractures. Close a measured food gap, and only then consider a small supplement.
- ☀️ What about vitamin D — should everyone take it? Test if you're at risk; correct if deficient. Above the floor, the large trials found no fracture benefit from routine dosing.
- 💊 My T-score is −2.6 — do I automatically need medication? Not automatically. The number opens the conversation; your age, fracture history, and ten-year probability decide it — with a clinician.
- ⏳ If I start a bisphosphonate, am I on it for life? Usually not — holidays after three to five years are standard practice when risk allows, decided by the same clinician who started it.
- 🧱 What should I do alongside any medication? The identical stack — load, protein, food-first calcium, and fall prevention. The drugs tilt the ledger; the lifestyle keeps the body that has to live with it.
The Bottom Line
- Food first, always — 1,000–1,200 mg of calcium a day from food is the target, and supplements have not prevented fractures in community-dwelling adults.
- Vitamin D is a correction, not a protocol — treat deficiency, skip megadoses, and don't expect fracture protection from routine dosing.
- Medication is for the high-risk tier — prior hip or vertebral fracture, T-score ≤ −2.5, or a ten-year probability over the line, with vertebral fracture reductions of roughly 47–73% across the pivotal trials.
- The tier is managed, not self-served — holidays, rebound rules, and sequencing are clinician territory, and the lifestyle stack runs underneath any prescription.
Related Topics
- Institute of Medicine, "Dietary Reference Intakes for Calcium and Vitamin D" (2011)
- Zhao JG et al., "Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults," JAMA (2017)
- Bolland MJ et al., "Calcium intake and risk of fracture: systematic review," BMJ (2015)
- LeBoff MS et al., "Supplemental vitamin D and incident fractures in midlife and older adults," New England Journal of Medicine (2022)
- Neale RE et al., "The D-Health Trial: a randomised controlled trial of the effect of vitamin D supplementation on mortality," Lancet Diabetes & Endocrinology (2022)
- Sanders KM et al., "Annual high-dose oral vitamin D and falls and fractures in older women," JAMA (2010)
- Black DM et al., "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures," The Lancet (1996)
- Black DM et al., "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis," New England Journal of Medicine (2007)
- Cummings SR et al., "Denosumab for prevention of fractures in postmenopausal women with osteoporosis," New England Journal of Medicine (2009)
- Cosman F et al., "Romosozumab treatment in postmenopausal women with osteoporosis," New England Journal of Medicine (2016)
- Neer RM et al., "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis," New England Journal of Medicine (2001)
- Eastell R et al., "Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline," Journal of Clinical Endocrinology & Metabolism (2019)